Abstracts

Effects of Tesamorelin on Hepatic Fat in HIV Patients: A Randomized Placebo-Controlled Trial

Background: Hepatic fat is often increased in HIV-infected patients with abdominal fat accumulation and may contribute to metabolic abnormalities. Currently, no strategies exist to reduce fat in this critical depot among HIV-infected patients. Tesamorelin, a growth hormone releasing hormone analogue, is FDA-approved for reduction of visceral fat in HIV, but its effects on hepatic fat…

Increasing Viral Suppression and Declining HIV/AIDS and Mortality in the Era of Expanded Treatment

Background: U.S. national data suggest that the number of new HIV diagnoses is roughly stable. However, within that stability, there may be substantial heterogeneity, with divergent trends occurring in different parts of the U.S. and in sub-populations within geographical areas. Methodology: We used data from the U.S. Census and the King County, WA HIV/AIDS Reporting…

BMI and CD4+ T-cell Recovery at 12 Months Among Adults Initiating ART in the United States and Canada

Background: Adipose tissue affects aspects of the cellular immune system, but prior studies have differed on whether a higher body mass index (BMI) promotes increased CD4+ T-cell recovery on antiretroviral therapy (ART). We used the multi-site NA-ACCORD dataset to analyze the relationship between pre-treatment BMI and 12 month CD4+ T-cell recovery among adults intiaiting ART…

Impact of Low-Level Viremia on Clinical and Virological Outcomes in Treated HIV Infected Patients

Background: The goal of antiretroviral therapy (ART) is to maintain undetectable viremia but the impact, particularly on clinical outcomes, of low-level viremia (LLV) between 50 and 500 cp/ml remains unknown. Methodology: We analysed data from 19 cohorts in Europe and North America contributing to the ART Cohort Collaboration (ART-CC). Included patients started ART (“baseline”) with…

Impact of Smoking on Life Expectancy Among HIV-Infected Individuals: The ART Cohort Collaboration

Background: Since the introduction ART non-AIDS related mortality rates (MR) in treated HIV positive people have exceeded AIDS-related MR, and the impact of smoking on life expectancy may have become substantial. Methodology: We estimated associations of smoking with mortality among treated HIV-infected patients, whose presumed transmission was not via IDU, enrolled in 8 cohorts in…

Impact of Three Different ART Regimens on the GALT: a Randomized Clinical Trial

Background: Acute HIV infection leads to depletion of the gastrointestinal-associated lymphoid tissue (GALT), driving bacterial translocation, chronic T-cell activation and disease progression. The aim of this study was to evaluate whether ART initiation regimen might determine mucosal recovery, and whether intensification with a fourth drug may achieve better immune reconstitution. Methodology: In this clinical trial,…

Impact of RAL/MVC Intensification With or Without HIV-rAd5 Vaccination on HIV DNA: ERAMUNE 02 Study

Background: HIV eradication may require synergistic interventions that purge latent reservoirs and increase the HIV-specific cellular immune response. DNA prime followed by recombinant adenovirus 5 boost vaccination (HIV-rAd5) has been shown to induce strong CD8+ cytotoxic T lymphocytes responses in HIV-infected and uninfected individuals. Methodology: Randomized, controlled, non-comparative clinical trial of ART intensification (raltegravir and…